The Clinical Research Circle
Brian Culley, CEO of Lineage Discusses Top Line Results For AMD
May 06, 2021
Benzinga Interview of CEO Brian Culley
Check out this exclusive Benzinga Interview with @LineageCell ($LCTX) and @CEO_Culley, as he discusses how they’re pioneering a new wave in #regenerativemedicine with their unique approach to #celltherapy.
Apr 20, 2021
Leadership Call Hosted by Chardan Capital Markets
Click to View
Apr 06, 2021
Sight & Sound Technology UK Webinar
Presentation by Brian Culley, Chief Executive Officer, Lineage Cell Therapeutics
Feb 10, 2021
Episode 45. Next generation of cell therapy – Feb 11, 2021
Scrip Asks…What Does 2021 Hold For Biopharma?
Scrip Informa Pharma Intelligence
Feb 9, 2021
Keeping Cell Therapy Clinicals On The Rails With Brian Culley
Feb 1, 2021
Tech Nation Radio on NPR
Dr. Moira Gunn speaks with Brian Culley, CEO, about Lineage’s cell therapy programs (segment begins at 38:08).
Jan 19, 2021
New Promise for Spinal-Cord Injuries
Genetic Engineering & Biotechnology News (GEN)
Jan 12, 2021
Cell Replacement Therapy – A Promising Treatment for Age-Related Macular Degeneration
Cell Science from Technology Networks Q&A with CEO Brian Culley
Dec 14, 2020
C-Suite Interview with CEO Brian Culley & CFO Brandi Roberts
Part of the Channelchek C-Suite Series, featuring exclusive interviews with small and microcap executives and the award-winning analysts from Noble Capital Markets.
Nov 2, 2020
Disruptive Technologies and Mature Regulatory Environment Vital for Cell Therapy Maturation
BioSpace article featuring Lineage Cell Therapeutics
Oct 16, 2020
Proactive One2One Virtual Investor Forum
CEO Brian Culley and CFO Brandi Roberts present to investors at Proactive’s One2One Virtual Investor Forum.
Oct 14, 2020
Cell and gene therapies tackle chronic conditions
BioWorld article featuring Lineage Cell Therapeutics
Oct 14, 2020
CEO Brian Culley and CFO Brandi Roberts joined Steve Darling from Proactive to share details about their proprietary cell-based therapy platform.
Oct 01, 2020
Force Wealth Fireside Chat
Jason McCarthy, Ph.D., Senior Managing Director covering biotechnology at Maxim Group joins Lineage Cell Therapeutics CEO, Brian Culley, and CFO, Brandi Roberts.
Sep 22, 2020
Empowered Patient Podcast
Injecting New Retina Cells into the Eye to Treat Age-Related Macular Degeneration with Brian Culley Lineage Cell Therapeutics
Sep 22, 2020
Interview of Brian Culley, CEO
Sep 10, 2020
The Simple BioTech Podcast
Cell Therapy & The Power of Pluripotent Stem Cells
Sep 3, 2020
Solebury Trout Talks
Data on OpRegen for Geographic Atrophy
Retina specialists discuss encouraging early results.
Jul 1, 2020
Presentations from specific events, conferences, or showcases
H.C. Wainwright & Co. Global Life Sciences Conference
Mar 9, 2021
Raymond James 42nd Annual Institutional Investors Conference
Mar 1, 2021
3rd Annual Longevity Therapeutics Conference
Applying Cell Therapy to Areas of Unmet Need. Presented by Brian Culley, Chief Executive Officer, Lineage Cell Therapeutics
Jan 28, 2021
Dr. Rob Rothman, the world’s leading ophthalmology investor, joins Brian Culley, CEO of Lineage Cell Therapeutics [LCTX], to discuss opportunities and new technologies for combatting eye disease.
FORCE Wealth Webinar
Jan 14, 2021
A fireside chat on Regenerative Medicine with Brian Culley, CEO, and Dr. Joseph Pantginis, Managing Director of Equity Research at H.C. Wainwright.
Dec 8, 2020
From Paralysis to Pitching – Improving Mobility After a Severe Spinal Cord Injury
Oct 22, 2020
H.C. Wainwright & Co. 22nd Annual Global Investment Conference
Sept 14, 2020
Solebury Trout Zoomside Chat
Joseph Pantginis from H.C. Wainwright discusses Lineage Cell Therapeutics (LCTX) with CEO Brian Culley and CFO Brandi Roberts
Sept 1, 2020
Force Wealth Webinar
July 30, 2020
2020 Solebury Trout Virtual Investor Conference
NobleCon16 Investor Conference Webcast
Key opinion leaders discuss topics related to Lineage’s clinical programs
Therapeutic Expert Call to Discuss OpRegen Phase 1/2a Study Interim Results (2020 American Academy of Ophthalmology Update)
November 17, 2020
Review of the pathogenesis of AMD and the pathways to CNV and GA
Jordi Monés, M.D., Ph.D., Director, Institut de la Màcula and Director, Principal Investigator and Founder, Barcelona Macula Foundation
New Retina Radio with Christopher D. Riemann, M.D.
Vitreoretinal Surgeon and Fellowship Director, Cincinnati Eye Institute
June 22, 2020
OpRegen® – A Discussion of Retinal Tissue Regeneration in Dry-AMD with Geographic Atrophy
June 8, 2020
Therapeutic Expert Call to Discuss OpRegen Phase 1/2a Clinical Study Results
Christopher D. Riemann, M.D. Vitreoretinal Surgeon and Fellowship Director, Cincinnati Eye Institute
May 11, 2020
OpRegen® Phase 1/2a Clinical Study Results
2020 ARVO Meeting
Christopher D. Riemann, M.D., Cincinnati Eye Institute (CEI)
Why is dry age-related macular degeneration (dry AMD) research so important?
Allen C. Ho, M.D., Wills Eye Hospital Director of Retina Research
Why is spinal cord research so important?
Dr. John Steeves, Emeritus Principal Investigator @ICORD and Professor @UBC
A selection of patient focused media related to our cell therapy programs
“New Treatment for Age-Related Dry Macular Degeneration” – May 10, 2021
ABC9 WPCO Cincinatti
Cell transplant therapy could be a treatment for leading cause of blindness – Feb 15, 2021
5 years through the eyes of a mum.
A powerful dramatization of living with the progression of vision loss related to AMD. Source: www.macularsociety.org
Spinal Cord Injury and Lineage’s OPC1 Cell Therapy
An instructive whiteboard video explaining how spinal cord injury disrupts normal bodily function as well as OPC1 administration and mechanism of action.
OPC1 Program – Patient Spotlight
Highlighting the progress made by Kris Boesen and Lucas Lindner, both of whom received Lineage’s OPC1 cell therapy following traumatic spinal cord injury (SCI).
Lucas Lindner was paralyzed from the neck down following a car accident. The next year, he threw out the first pitch at a Major League Baseball game.
Watch the video above to learn more about Lucas’ journey.